Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Photodynamic Molecular Beacons: an Image-Guided Therapeutic Approach for Vertebral Metastases
EF 2008-09
Résumé
Breast cancer is the second leading cause of cancer death in women. 85% of breast cancer-related deaths have evidence of vertebral metastases. Current therapies are limited by the high associated risk of spinal cord damage.Thus, the need for a new treatment is becoming increasingly evident. Photodynamic therapy (PDT) in combination with surgical techniques such as vertebroplasty, presents an attractive alternative due to its minimally invasive nature, selectivity and minor associated side effects. PDT destroys cells when light activates a photosensitizer (PS) in the presence of oxygen, initiating a photochemical reaction which produces singlet oxygen (1O2). By controlling the delivery of light and PS to tumor tissues, some degree of PDT selectivity is achieved. A limitation of current PS is its ability to accumulate a high concentration in the tumor but not in surrounding tissues. This is especially critical in treating vertebral bone metastases due to the proximity of the spinal cord to the vertebrae. Thus, current PDT treatments are limited by the amount of normal tissue damage.
We developed a novel photodynamic molecular beacon (PMB) concept that provides an unprecedented level of PDT selectivity. PMBs consist of a peptide linker that is sequence specific to a cancer-associated protease, a PS and a 1O2 quencher. Photo-activity is inhibited until in the presence of the target protease. Thus, the ability of a PS to generate 1O2 can be switched on/off depending on specific linker-target interactions. This enables PMBs to achieve an unprecedented level of PDT selectivity, destroying only targeted cancer cells, and leaving non-targeted cells unharmed. Initial studies are demonstrating an additional level of PDT control with PMBs. PMBs have the potential to become the most effective treatment for advanced stages of breast cancer. Successful completion of my project could pave the way to expand this modality to treat other cancers using specific-disease biomarkers.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
184508
Name
Liu Tracy W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Photodynamic Molecular Beacons: an Image-Guided Therapeutic Approach for Vertebral Metastases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Activatable Photosensitizers; Biodistribution Studies; Biophotonics; Cancer Biomarkers; Cancer Metastasis; Enzyme Kinetics; In Vivo Imaging & Fluorescence Guidance; Photodynamic Therapy; Protein Synthesis & Characterization; Targeted Drug Therapy
Abstract
Breast cancer is the second leading cause of cancer death in women. 85% of breast cancer-related deaths have evidence of vertebral metastases. Current therapies are limited by the high associated risk of spinal cord damage.Thus, the need for a new treatment is becoming increasingly evident. Photodynamic therapy (PDT) in combination with surgical techniques such as vertebroplasty, presents an attractive alternative due to its minimally invasive nature, selectivity and minor associated side effects. PDT destroys cells when light activates a photosensitizer (PS) in the presence of oxygen, initiating a photochemical reaction which produces singlet oxygen (1O2). By controlling the delivery of light and PS to tumor tissues, some degree of PDT selectivity is achieved. A limitation of current PS is its ability to accumulate a high concentration in the tumor but not in surrounding tissues. This is especially critical in treating vertebral bone metastases due to the proximity of the spinal cord to the vertebrae. Thus, current PDT treatments are limited by the amount of normal tissue damage.
We developed a novel photodynamic molecular beacon (PMB) concept that provides an unprecedented level of PDT selectivity. PMBs consist of a peptide linker that is sequence specific to a cancer-associated protease, a PS and a 1O2 quencher. Photo-activity is inhibited until in the presence of the target protease. Thus, the ability of a PS to generate 1O2 can be switched on/off depending on specific linker-target interactions. This enables PMBs to achieve an unprecedented level of PDT selectivity, destroying only targeted cancer cells, and leaving non-targeted cells unharmed. Initial studies are demonstrating an additional level of PDT control with PMBs. PMBs have the potential to become the most effective treatment for advanced stages of breast cancer. Successful completion of my project could pave the way to expand this modality to treat other cancers using specific-disease biomarkers.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Liu, Tracy W
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~